Canada approves generic version of Wegovy for weight loss

OTTAWA – Health Canada has approved a generic version of Wegovy, a semaglutide drug that’s prescribed to help people lose weight.

The weekly injection is known as Sevmia from the Canadian company Apotex and is pharmaceutically equivalent to weight-loss medication Wegovy from Denmark’s Novo Nordisk.

Health Canada says Sevmia can be prescribed to people 12 years of age and over, as a supplement to a reduced-calorie diet and increased physical activity for weight management.

It’s the third generic semaglutide medication approved by the department, though the first two were authorized for the treatment of Type 2 diabetes in adults.

Generic versions of Novo Nordisk’s Ozempic by India-based Dr. Reddy’s Laboratories and Apotex were approved earlier this year. At the time, Apotex said its generic would be approximately one-third the price of Ozempic.

Health Canada says it’s reviewing six other submissions for generic semaglutide from different companies and expects to make more decisions in the coming weeks and months.

According to the pricing structure of the pan-Canadian Pharmaceutical Alliance, when two generic medications enter the market, they are at least 50 per cent cheaper than the brand name — but companies can price them lower.

Experts have previously estimated the cost of Wegovy to be around $400 a month, though prices can vary by dose and location. 

“The availability of generic drugs is expected to have a positive impact in Canada, including potential cost savings for patients and the health-care system,” the federal agency said in a news release Monday. 

This report by The Canadian Press was first published June 29, 2026.

Note to readers:This is a corrected story. A previous version misspelled Sevmia based on a press release.